Purpose: To determine the inclusion of women and the sex-stratification of results in moxifloxacin Clinical Trials (CTs), and to establish whether these CTs considered issues that specifically affect women, such as pregnancy and use of hormonal therapies. Previous publications about women's inclusion in CTs have not specifically studied therapeutic drugs. Although this type of drug is taken by men and women at a similar rate, adverse effects occur more frequently in the latter. Methods: We reviewed 158 published moxifloxacin trials on humans, retrieved from MedLine and the Cochrane Library (1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010), to determine whether they complied with the gender recommendations published by U.S. Food and Drug Administration Guideline. Results: Of a total of 80,417 subjects included in the moxifloxacin CTs, only 33.7% were women in phase I, in contrast to phase II, where women accounted for 45%, phase III, where they represented 38.3% and phase IV, where 51.3% were women. About 40.9% (n = 52) of trials were stratified by sex and 15.3% (n = 13) and 9% (n = 7) provided data by sex on efficacy and adverse effects, respectively. We found little information about the influence of issues that specifically affect women. Only 3 of the 59 journals that published the moxifloxacin CTs stated that authors should stratify their results by sex. Conclusions: Women are under-represented in the published moxifloxacin trials, and this trend is more marked in phase I, as they comprise a higher proportion in the other phases. Data by sex on efficacy and adverse effects are scarce in moxifloxacin trials. These facts, together with the lack of data on women-specific issues, suggest that the therapeutic drug moxifloxacin is only a partially evidence-based medicine.
Introduction
F luoroquinolone antibiotics are surrounded by controversy due to their adverse effects, some of which occur more frequently in women, such as QT-interval prolongation, which can lead to torsades de pointes 1 or cutaneous photosensitization. 2, 3 In addition, moxifloxacin has been the center of extensive debate since its authorization, mainly due to the alleged advantages it has over other drugs in its class and also due to the increased risk of cardiac disorders. 4 Interestingly, the U.S. Food and Drug Administration (FDA) approved moxifloxacin despite the objections raised by some members of the FDA advisory committee and the medical review officer. 5 Lastly, the FDA and European Medicines Agency (EMA) have approved its use in uncomplicated gynecological infections; a decision that has been criticized since authorization was based on a single randomized, double-blind controlled trial with 741 patients over 6 weeks. Thus, the potential for long-term complications such as infertility or extra-uterine pregnancy are unknown. 4 Some fluoroquinolones have been withdrawn from the market in certain countries due to serious adverse events and safety concerns. These include temafloxacin (in 1992), which has been shown to cause hemolytic anemia, often accompanied by renal or hepatic dysfunction and/or coagulopathy 6 ; trovafloxacin and alatrofloxacin (2001), which cause fatal liver damage 7 ; grepafloxacin (2003) , which produces adverse effects related to prolongation of the QT interval on the electrocardiogram, leading to cardiac events and sudden deathmore frequently in women than men 8 ; and gatifloxacin (2006), since it increases risk of diabetes, hallucinations, liver damage, and purpura. 9 Other quinolones, including moxifloxacin, have had their licensed indications restricted due to toxicity issues. 10 In 2008, alerted by the serious risks involved in the use of oral moxifloxacin, the EMA and FDA analyzed pharmacovigilance data. 7, 11 The EMA decided that moxifloxacin should only be prescribed in the treatment of acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and community-acquired pneumonia when other antibiotics cannot be used or have failed. Furthermore, the FDA has stated that 1 moxifloxacin shows no advantages over other antibiotics and moreover has been observed to entail a higher cardiovascular risk in women than in men.
Despite the problems associated with taking fluoroquinolones, they are now the most commonly prescribed class of antibiotics in adults. 12 Nearly half of these prescriptions are to treat non-approved conditions. 12 Despite the restrictions on its use, moxifloxacin has become a bestseller for Bayer-accounting for 497 million Euros ($697.3 million) worldwide in 2010. 13 In 1993, the FDA published its Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, aimed at promoting not only the inclusion of women in clinical trials (CTs) but also the analysis of gender differences. 14 There has been an increase in the number of studies which have since examined the inclusion of women in CTs and conducted analyses by sex. These studies found that women only represent around 20% of subjects included in CTs of drugs for specific diseases, 15 published in high impact factor journals, [16] [17] [18] or funded by public institutions. 19 Lastly it has been demonstrated that CTs of some drugs, such as antiretrovirals 20 and aripiprazol 21 have included fewer women than men. In contrast, CTs of other drugs have included more women than men, particularly in the case of anti-inflammatory drugs, 22, 23 which were withdrawn from the market following fatalities. However, women were significantly under-represented in the crucial first phase, 22, 23 where the objective is to evaluate the safety of the drug. It has been explained on the basis of the potential risk of fetal harm should women become pregnant during the CT. 24 Other explanations for the exclusion of women in the CTs reported in the literature include the confounding effects related to the hormonal cycle, the higher withdrawal rate of women and interactions with other hormonal treatments. 24 Due to pressure from the U.S. FDA and National Institutes of Health (NIH), feminist movements, and other lobby groups, women are now better represented in sample sizes. Nevertheless, one form of measurement bias persists as 75% of CTs that receive federal funding from NIH, 25 and up to 95% of CT reports to the Spanish Medical Agency 26 do not include sex stratification. If analyses by sex is not considered in the design phase, it is possible that, in the subsequent analysis phase, the overall sample sizes are too small to produce valid results by sex.
The aims of this study were to determine compliance of moxifloxacin CTs with published good practice guidelines for sex and clinical trials 14 and to explore editorial policies on sex differences and women-specific issues in the journal of publication. The rationale for choosing moxifloxacin was that previous publications have not specifically studied therapeutic drugs, such as antibiotics, where the benefit-risk profile differs from that of symptomatic medications. Furthermore, this drug belongs to a group of antibiotics that is consumed by both sexes to the same degree although the adverse effects occur more frequently in women. 27 ,28
Methods
We conducted a review of moxifloxacin clinical trials, using as keywords ''moxifloxacin'' and ''avelox,'' and as limits ''humans,'' in Medline and the Cochrane Library. We identified a total of 173 trials published between January 1998 and December 2010 described in 172 papers of moxifloxacin on adults, published in English (171) and Spanish (1) and excluded those that gave no information about the number or frequency of women and men in the sample (15) . Consequently, we retrieved and analyzed a total of 158 CTs (Fig. 1) .
In order to conduct a sex analysis of the CTs reviewed, we designed a protocol in accordance with the recommendations of the Food and Drug Administration (FDA) Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs, 14 which included the following variables:
1. Demographic characteristics: inclusion frequencies for women and men, age (range, or failing that, mean), type of patient (healthy or type of infection).
CT phase
Phase I: to test an experimental drug or treatment in a small group of people for the first time, to gather preliminary data on the agent's pharmacodynamics and pharmacokinetics, and to evaluate its safety, determine a safe dosage range, and identify side effects; Phase II: the experimental treatment is given to a larger group of people to see if it is effective and to further evaluate its safety; Phase III: treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow it to be used safely; and Phase IV: post-marketing studies delineate additional information, including the treatment's risks, benefits, and optimal use.
3. Objective/s of the clinical trials. 4. Limiting omissions (from the gender perspective interest). 5. Sex differences: discussion of the results by sex. Data stratified in order to enable gender analysis of the results. Analysis by sex of efficacy, adverse effects, doseresponse, blood concentration-response. 6. Women-specific issues: pregnancy as an exclusion criterion, use of contraceptive methods, use of hormonal contraceptives, and use of hormone replacement therapy (HRT). 7. Excluded from the analysis: editorial policies on sex differences and women-specific issues in the journal of publication.
We analyzed the frequencies and percentages of the variables described above. The main criterion for considering whether a clinical trial fulfilled a sex-related recommendation was any mention of the sex variable in the text. The level of inter-observer agreement (authors E.C. and M.T.R.) was calculated by means of the Kappa index, and a high level of agreement was obtained (Kappa index: 95%). Any lack of agreement (5%) was resolved by a third researcher (A.P.).
The criteria used for the inclusion of clinical trials under each analysis variables were not mutually exclusive ( Fig. 1): ‚ Sex stratified data and discussion of results by sex: CTs that include both sexes (127 CTs), excluding those that only included one sex or the other. ‚ Efficacy by sex: CTs that included both sexes and gave efficacy as an objective (85 CTs). ‚ Adverse effects by sex: CTs that included both sexes and gave information about adverse effects (78 CTs). 
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‚ Effect of moxifloxacin on QT interval: CTs that included both sexes and studied the QT interval after moxifloxacin administration (53 CTs). ‚ Dose response relationship: CTs that included both sexes and analyzed the dose-response relationship (10 CTs). ‚ Blood concentration by sex: CTs that included both sexes and gave an analysis of the dose-response relationship among their objectives (46 CTs).
For the following variables, only CTs that included women of childbearing age were considered in the analysis: Pregnancy as an exclusion criterion, recruitment of women using a contraceptive method or hormonal contraception, interaction between moxifloxacin and hormonal contraception.
CTs that included women at menopausal age were included in the analysis of recruitment of women taking HRT, evaluation of interaction of the drug and HRT. CTs including women were considered in the analysis of the influence of ovarian cycle status on drug pharmacokinetics.
To determine whether a CT included women of childbearing age or women of menopausal age, we used the study population age data provided by the CTs. Tables 1 to 4 show the number of subjects (% women) and characteristics of study subjects for 69 phase I CTs (Table  1) , 30 phase II CTs (Table 2) , 49 phase III CTs ( Table 3) , and 10 phase IVCTs [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] (Table 4 ). The titles of the journals that published the 158 CTs reviewed also appear. A total of 80,417 individuals participated in the CTs studied, 46.6% (37,474) of whom were women. The frequency of healthy subjects was 1,021 (31% women), while 68,289 had some kind of respiratory infection (46.8% women), 2,082 had eye infections (51.2% women), 1,964 had gastrointestinal infections (47.9% women) and 6,803 suffered other diseases (13.8% women).
Results
Thirty-one CTs were conducted on one sex alone: 23 phase I CTs were performed with 436 men and 3 CTs with 99 women; 3 phase II CTs were conducted with 52 men; and 2 phase III CTs with 1,427 women. Figure 2 shows that women made up 33.7% of the enrollment in the 69 phase I CTs, 45% of the 30 phase II CTs, 38.3% of the 49 phase III CTs, and in 51.3% of the 10 phase IV CTs.
Fifty-two (40.9%) of CTs stratified randomization by sex, accounting for 42.7% of the women (n = 15,361 women) included as study subjects in the CTs (Table 5 ). Only 8 CTs (5.5%) discussed the results by sex (Table 5) .
Of the 85 CTs studying efficacy, 15.3% (n = 13) conducted an analysis by sex (Table 5) . Specifically, 11% of women and 10.8% of men were included. The results of these CTs showed that 11 CTs did not detect any differences (Table 5) , 1 CT detected sex differences at the time of peak serum bactericidal activity, and 1 CT found the drug to be more effective in men than in women. Nine percent (n = 7) of the 78 CTs that studied adverse effects conducted an analysis by sex (Table 5 ). These CTs included 42.7% of women, compared with 28.2% of men. However, only 3 CTs (7.4%) analyzed the QT interval by sex, accounting for 1.7% of study subjects of both sexes (269 women and 308 men): 1 CT did not detect significant differences between men and women, but 2 reported increased QT intervals in women (Table 5) .
No sex differences were detected in the 3 CTs (8.7%) that analyzed blood concentration by sex (Table 5 ) and included 1.7% of study subjects of both sexes (25 women and 77 men). None of the CTs studied dose response by sex. Table 5 shows the FDA recommendations related to women-specific issues. The most frequently observed recommendation was to consider pregnancy as an exclusion criterion in women of childbearing age, used in 52.1% of CTs (n = 60). Regarding the recommendations related to contraception, 18.3% of CTs (n = 21) included the recommendation to take measures to avoid pregnancy during the trial (either barrier or hormonal contraceptive methods). These CTs only included 13.5% (n = 4,907) of women participating in CTs with women of childbearing age.
Only 3 CTs mentioned the inclusion of women using hormonal contraceptives (64 women) ( Table 5 ). Furthermore, only 2 CTs conducted a comparison of women taking hormonal contraception and those who were not and analyzed the possible interactions between hormonal contraceptives and moxifloxacin (59 women) ( Table 5 ). None of the CTs involving women of menopausal age specified whether the women were taking HRT. One CT studied the influence of menstrual status, including a comparison between pre-and postmenopausal women ( 
Discussion
The main findings of this review of published CTs on moxifloxacin were that fewer women participated in phase I trials. This is significant, as results from this initial phase are used to determine dosage in subsequent phases. The study also revealed that CTs that examined adverse effects included more women than men, and that although a considerable number of CTs stratified by sex in the design phase, only a very small proportion analyzed the results by sex. Moreover, very little attention was paid to the influence of hormones on the action of moxifloxacin. Although an increasing number of policies exist aimed at ensuring the inclusion of women in CTs and the analysis of sex differences, and organizations such as the FDA, NIH, 185 or the General Accounting Office 186 have made considerable efforts in this respect, in practice implementation of such policies is still insufficient according to the information published on CTs of therapeutic drugs such as moxifloxacin.
Since the CT is the paradigm of clinical research, and the fundamental tool for evaluating drugs, the distribution of CT patients by sex should reflect the population of patients that will use the drug once it is on the market. 14 The moxifloxacin CTs included equal numbers of men and women, coinciding with the number of users according to phase IV or postmarketing data. 147, [178] [179] [180] [181] [182] [183] [184] [185] [186] However, women were underrepresented in phase I, which implies the loss of information necessary for the design of subsequent CT phases. 18 
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CHILET-ROSELL ET AL. Did not include women Objective of phase 3: treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it with commonly used treatments, and collect information that will allow it to be used safely. AECB, Acute exacerbation of chronic bronchitis; COPD, chronic obstructive pulmonary disease; HAP, hospital acquired pneumonia; i.v., intravenous; p.o., oral. Few CTs conducted an analysis of efficacy by sex, and these included only a small proportion of men and women with respect to the total number of efficacy CTs. This raises the question of whether failure to take sex into account in the design of the sample size reduces a CT's power to detect differences between the two sexes in the subsequent sex-stratified analysis. The case of the adverse effects of moxifloxacin is different. Although few CTs were aimed at identifying adverse effects by sex, these did include a high proportion of both men and women. The results of these CTs were heterogeneous and thus no specific conclusions can be drawn. The variability of results for the occurrence of adverse effects is important, since women have been reported to experience adverse effects with greater frequency. 187 Specifically, four CTs found no sex differences. 47, 65, 181, 183 In contrast, one CT identified being male as a risk factor, 142 whereas another reported better tolerance in men. 182 One CT 178 reported the possibility of paralytic ileus in one woman, and six women and three men presented mild-to-moderate effects on their central nervous system in another. 27 The Summary of Product Characteristics (SPC) 3 for moxifloxacin indicates that women may be more sensitive to drugs that prolong the QT interval; however, only a few trials have studied differences by sex for this effect. This may be because the effect is already known. 188 The SPC for moxifloxacin indicates that plasma concentration may be higher in women, 3 although the published moxifloxacin CTs did not give pharmacokinetic data by sex.
As regards women-related issues, the use of moxifloxacin is contraindicated in pregnancy, since reversible joint damage has been described in children who had absorbed quinolones. 3 Furthermore, although the reproductive toxicity of moxifloxacin in humans is unknown, other fluoroquinolones have been associated with an increased frequency of miscarriage in pregnant women. 189 According to this information, all CTs that include women of childbearing age should specify pregnancy as an exclusion criterion. However, nearly half did not provide information on whether pregnancy was used as an exclusion criterion, let alone whether subjects were required to take steps to avoid pregnancy during the CT.
The possible influence of hormones on the results of the published moxifloxacin CTs is barely addressed, and thus there is a clear lack of information on the concomitant use of this drug and HRT. When reporting data about interactions between hormone levels and moxifloxacin, the information was sometimes incomplete. This was the case with one CT, which indicated that the use of oral contraceptives was permitted but did not report whether any of the women subjects were taking them nor analyzed the possible effect. 63 According to the study by Stass, moxifloxacin does not interfere with hormonal contraception 72 ; however, another study found that hormonal contraceptives lowered the plasma concentration of moxifloxacin, which is an important consideration when treating for pathogens with ''borderline susceptibility'' to moxifloxacin. 76 Interestingly, the SPC does not mention the interaction between moxifloxacin and hormones. 3 The pharmaceutical industry has made valuable contributions to the effective treatment of certain diseases and should therefore be an authority on the subject. Consequently, it is difficult to understand why it would risk losing credibility by not complying with recommendations such as considering an analysis by sex in the discussion sections of related articles. This information is easy to include but was only provided in a handful of articles on moxifloxacin. Two of these articles acknowledged that although sex-related differences had been detected, the results were of limited value due to the insufficient number of women included in the trial. 68 In one CT, the authors reported being unable to explain the significance of the sex difference detected in time of peak serum bactericidal activity. 70 Another reported an already well-known difference, namely that being male is a risk factor for mortality in community-acquired pneumonia. 142 A further three CTs mentioned in their discussion sections that no sex-related differences had been detected. 72, 65, 144 Regulatory bodies and funding agencies should devise new programs or strategies to improve representation of both sexes in CTs and should oblige researchers to consider sex differences during data analysis. Together with public health authorities, the pharmaceutical industry is facing the new challenge of protecting health by implementing actions that comply with the codes of good scientific practice. As the Canadian Medical Research Council's Advisory Committee on Women in Clinical Trials has suggested, if information is provided by sex for each clinical trial, it would be possible to conduct meta-analyses to determine how women respond to a particular drug. 190 Furthermore, Paula A. Rochon has proposed the publication of subgroup analyses of men and women to facilitate meta-analysis. 15 The recently published CONSORT statement 191 has missed the opportunity to include recommendations from a gender perspective, which would have been decisive in preventing methodological biases in study designs and analyses that limit the accuracy and extrapolation of the findings. 192 In the case of moxifloxacin CTs, only three journals (Current Medical Research Review, Ophthalmology, PLoS One) mentioned this requirement. Although it is possible that many CTs are well designed, based on an adequate number of patients, and include an analysis by sex of the data, this information is not published, perhaps because the researchers did not consider the information to be relevant when they detected no differences. We could improve this situation if scientific journals were to recommend (or oblige) authors to present such data in their editorial instructions, or if the authors were at least to state whether they had conducted (or not) an analysis by sex, and if so, that the results would be made available on request. Knowing that CT results reveal no sex-related differences is also important. Nevertheless, it would be useful to provide incentives to researchers to publish these results separately, and to train junior researchers and students in the skills necessary to analyze CT results, identify the omissions that have occurred (or can occur) and recognize exemplary studies.
The study did have some limitations. As the study was based on the sex differences and gender analyses reported in published clinical trials of moxifloxacin indexed in Medline and the Cochrane Library, it has not covered other relevant characteristics that are worthy of investigation, such as age and ethnicity. In addition, we cannot be totally sure that data by sex is not held by the regulatory authorities or pharmaceutical companies concerned. However, previous studies on reports submitted by pharmaceutical companies to regulatory authorities have indicated that this information does not exist, 26, 193 and the main regulatory agencies have no authority (legal means) to compel disclosure of drug effects by gender.
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